Growth hormone secretion elicited by GHRH, GHRP‐6 or GHRH plus GHRP‐6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy

Popović, Vladimir; Simić,; Ilic, Ljubomir M.; Micic,; Damjanovic,; Djurovic,; Obradović,; Diéguez, A.; Casanueva,

doi:10.1046/j.1365-2265.1998.00360.x

Cited by 14 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mechanisms of pituitary function recovery following medical therapy may include tumour shrinkage or relate to re‐establishing hypothalamic control. Popovic et al . (1998) have shown that GH secretion in response to GH releasing peptide 6 (GHRP‐6) improved in patients with macroprolactinomas following therapy with bromocriptine for 6–24 months while the response to growth hormone releasing hormone (GHRH) was unchanged.…”

Section: Discussionmentioning

confidence: 99%

Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas

George

Nicolau

Scanlon

et al. 2000

Clinical Endocrinology

View full text Add to dashboard Cite

These data indicate that growth hormone secretion may recover following successful reduction of prolactin levels after cabergoline therapy for a mean of 22 months (range 6-28 months) in most but not all subjects with a macroprolactinoma. It is therefore advisable that individuals with a macroprolactinoma in whom growth hormone replacement therapy is being considered undergo repeat assessment of growth hormone secretion following medical treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas

George

Nicolau

Scanlon

et al. 2000

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Furthermore, obese children provide high levels of IGF-1 and growth because of insulin, even after hypophysectomy [20,21,22]. Popovic et al [21] demonstrated fully preserved GH release after GHRP-6 or GHRH+ GHRP-6 stimulation in patients with microprolactinomas, before and after treatment. Patients with macroprolactinoma have blunted responses of GH.…”

Section: Discussionmentioning

confidence: 99%

Hyperprolactinemia: Different Clinical Expression in Childhood

Šaranac¹,

Živanović²,

Radovanović

et al. 2010

Horm Res Paediatr

View full text Add to dashboard Cite

Background: Hyperprolactinemia is the most common disturbance in pituitary gland secretion. Functional diversity of prolactin action is responsible for different initial clinical expressions of hyperprolactinemia. Patients and Methods: We investigated causes of hyperprolactinemia in 11 children and adolescents (6 females and 5 males), aged from 1.5 to 17.5 years. Children with primary hypothyroidism, iatrogenic hyperprolactinemia and adolescents with polycystic ovaries were excluded. Results: Four patients had short stature or growth deceleration, the same number were clinically obese, 2 adolescent girls had secondary amenorrhea, 1 girl had premature thelarche and gynecomastia, and hypogonadism was the indication for the endocrinologic examination of two adolescent boys. Delayed pubertal development was present in both sexes. Hyperprolactinemia was also found in the youngest girl with multiple ovarian cysts. A very high prolactin (PRL) level was documented in the PRL profile of all patients (mean 2,553.00 ± 1,020.97 mU/l). MRI of the pituitary was indicated and revealed 4 microprolactinomas, one congenital hypophyseal cyst and one tumor of the hypothalamus. Dopamine agonist treatment was efficacious in almost all the patients. Conclusion: Hyperprolactinemic children expressed a wide variety of initial clinical presentations. The most common were growth and puberty disorders and obesity. PRL determination should be included in investigation protocols of obese and short stature children.

show abstract

“…It is useful to repeat the MRI 2–3 months after starting therapy and at longer intervals thereafter. Several studies have demonstrated recovery of impaired anterior pituitary function in association with tumour shrinkage 31 and ovulatory menses return in over 90% of premenopausal women. Dopamine agonists usually restore visual function to an extent similar to that produced by surgical decompression of the chiasm in macroprolactinoma patients.…”

Section: Medical Treatment Of Prolactinomasmentioning

confidence: 99%

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas

Casanueva

Molitch

Schlechte

et al. 2006

Clinical Endocrinology

726

635

View full text Add to dashboard Cite

SummaryIn June 2005, an ad hoc Expert Committee formed by the Pituitary Society convened during the 9th International Pituitary Congress in San Diego, California. Members of this committee consisted of invited international experts in the field, and included endocrinologists and neurosurgeons with recognized expertise in the management of prolactinomas. Discussions were held that included all interested participants to the Congress and resulted in formulation of these guidelines, which represent the current recommendations on the diagnosis and management of prolactinomas based upon comprehensive analysis and synthesis of all available data.

show abstract

Growth hormone secretion elicited by GHRH, GHRP‐6 or GHRH plus GHRP‐6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy

Cited by 14 publications

References 20 publications

Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas

Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas

Hyperprolactinemia: Different Clinical Expression in Childhood

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas

Contact Info

Product

Resources

About